Highly specialised technologies evaluation committee members

Find out more about the highly specialised technology evaluation committee members by reading their biographies.

Dr Paul Arundel (chair)


Paul is a full-time NHS consultant and clinical lead for the Paediatric Metabolic Bone Disease Service at Sheffield Children’s Hospital. His work encompasses the delivery and improvement of care to children and young people with a wide range of bone diseases through multidisciplinary team working and collaboration with partners across the UK.

He has overseen the implementation of the Highly Specialised Services for both “severe, complex and atypical osteogenesis imperfecta” and “paediatric-onset hypophosphatasia”.

Clinical and research interests include assessment and treatment of bone fragility disorders, achondroplasia and disorders of calcium and phosphate metabolism including X-linked hypophosphataemic rickets.

Professor Iolo Doull (Vice-Chair)


Iolo is the Executive Medical Director of the Welsh Health Specialised Services Committee, responsible for the commissioning of specialist medical services to the population of Wales.

He was previously a consultant respiratory paediatrician at the Children’s Hospital for Wales and clinical lead for specialist paediatric respiratory services in South and Mid Wales He is the chair of the All Wales Medicines Strategy Group, which advises Welsh Government on the use, management and prescribing of medicines in Wales, and chair of the Wales Rare Diseases Implementation Group responsible for overseeing the Rare Diseases National Plan in Wales. He was an expert advisor on the NICE cystic fibrosis guideline, and an expert advisor to the Commission on Human Medicines.

He has previously been President of the British Paediatric Respiratory Society Health, and Royal College of Paediatrics and Child Health Officer for Wales. He has chaired a Research Ethics Committee for over 10 years.

Ms Annett Blochberger, MPharm, DipPharmPrac


Annett is deputy head of London’s Specialised Commissioning Pharmacy team at NHS England. Here she manages a high cost medicines portfolio of significant value which is invested through London NHS Trusts for the delivery of specialised services. Her work ensures use of these medicines within services promotes quality, efficiency and represents value for money. Prior to her appointment at NHS England, she worked for several years in various commissioning roles on behalf of Clinical Commissioning Groups and within one of the largest NHS trusts in England, working with multiple stakeholders to improve patient access and outcomes to services, and cost-effectiveness to the NHS.

As a clinical pharmacist, Annett has a broad range of experience across a number of clinical specialties: neurosciences, ophthalmology, haematology, rheumatology, gastroenterology and dermatology. She is currently the chair of the medical data solutions and services (MDSAS) Data and Referral Group, steering the clinical data requirements needed to effectively drive immunoglobulin stewardship across England. Annett is also co-chair of the London Circular and Policy Implementation Group which governs the implementation of NHS England commissioning policies at regional level.

In her previous role as lead pharmacist for neurosciences at St George’s University Hospitals NHS Foundation Trust, she led and expanded the clinical pharmacy service to patients with neurological conditions and was a founding member of the UKCPA Neurosciences Group which holds a strong focus on clinical education and networking.

Annett is a Chief Pharmaceutical Officer’s clinical fellow (2019 to 2020) and has been a NICE medicines and prescribing associate between 2018 and 2023.

Emtiyaz Chowdhury


Emtiyaz is a principal consultant in health economics at Parexel, a clinical research organisation which offers market access consulting services to the life science industry. He oversees a team of economists and statisticians to develop health economic models and prepare written materials to support submissions to health technology assessment bodies including NICE.

Prior to his work in market access consulting, Emtiyaz worked as a health economist at the Royal College of Physicians (National Guidelines Centre) who were commissioned by NICE to develop clinical guidelines. As a member of the technical team, Emtiyaz advised NICE’s guideline committees to incorporate health economic evidence into their recommendations.

Emtiyaz holds an MA from University College London in Philosophy, Politics and Economics of Health and a BSc in Biological Sciences (Physiology and Pharmacology) from the University of Leicester.

Sarah Davis


Sarah is a Senior Research Fellow in Health Economics based at the School of Health and Related Research (ScHARR) at the University of Sheffield and is a member of the ScHARR Technology Assessment Group. Her technical background is in cost-effectiveness modelling and she has a particular interest in patient-level simulation.

Sarah was previously deputy director of ScHARR’s Decision Support Unit, which is commissioned by NICE to provide a research and training resource to support the Technology Appraisal Programme. Prior to her role at ScHARR, she was Health Economic Lead at the National Clinical Guideline Centre, which is commissioned by NICE to develop clinical guidelines.

Carrie Gardner


Carrie is the regional programme of care lead for internal medicine for NHS England (London Region). She has responsibility for service areas such as cardiac, vascular, renal and specialised respiratory services. She has worked in operational commissioning roles in London since the establishment of NHS England. She has a background in clinical audit and in the private sector.

Carrie was previously the lead commissioner for the cardiac services Clinical Reference Group which has developed national commissioning products such as clinical commissioning policies, quality dashboards and improving value schemes.

Tina Garvey


Tina Garvey is Chief executive at Retina UK. Since joining the charity, in 2015, the organisation has grown so the team can provide even more information and support services, and work toward funding more medical research to find effective treatments for inherited progressive sight loss conditions.

Playing an active role within the vision sector, such as co-chairing the Vision UK Research Cures & Treatment Panel and becoming a liveryman of the Worshipful Company of Spectacle Makers. Tina has raised the profile of Retina UK, not only in the charity sector, but also through professionals, individuals and families close to inherited sight loss creating tangible benefit to those families and individuals the charity represents. She leads a team committed to making sure that our community is being heard, is getting the very best information and services and that the charity has the greatest possible impact.

Tina has 15 years' experience in the charity and public sector; before becoming the Chief executive at Retina UK, Tina ran the east and north Herts NHS Hospitals' Charities for over five years and before that held senior fundraising roles in national charities. Tina has a BSc in Science and Social Sciences, a postgraduate diploma in Marketing, an MSc in Leadership and Management in Public Services and is currently working toward the SQE law qualification.

Tina is also a trustee for the BDCI charity.

Professor Jonathan Ives


Jon is Professor of Empirical Bioethics and Deputy Director of the Centre for Ethics in Medicine, Bristol Medical School, as well as Head of Section for Health Care Evaluation. He initially trained in philosophy, and now works as an interdisciplinary bioethicist at the nexus of ethics and social science, with a particular focus on empirical bioethics methodology, on which he has published widely and delivers training worldwide.

His research interests are varied and include surgical innovation; ethics and trust of AI with evolving functionality; best interests decision making; clinical and research ethics; ethics, reproduction and parenthood. His work has been funded by, for example, the Wellcome Trust, NIHR, EPSRC, ESRC, AHRC.

He has published on a wide range of topics including ethics and fatherhood, research ethics, technology and innovation, end of life ethics, and clinical ethics, and he is lead editor of 'Empirical Bioethics: Theoretical and Practical Perspectives' (Cambridge University Press).

Stuart Mealing


Stuart is an associate director of York Health Economics Consortium and leads the consortium’s health economic modelling and outcomes research (HEOR) workstream.

Stuart has a master’s degree in operational research from the University of Lancaster business school and a postgraduate qualification in international business management from Smurfit Business School in Dublin. He has worked in numerous therapy areas including oncology (solid tumour and haematological), cardiology (devices and pharmaceuticals), pulmonology, ophthalmology and neurology.

Stuart has extensive experience in the development and review of cost-effectiveness and budget impact models, and has particular experience in working with orphan/ultra-orphan conditions as well as the use of a range of survival analysis techniques. Stuart also has experience of performing and managing a range of projects covering statistical data analysis, evidence synthesis, literature review and the development of reimbursement submissions.

Dr Shehla Mohammed MD, FRCP


Shehla is honorary senior lecturer in clinical genetics, King’s College Hospital, and Guy’s and St. Thomas’ NHS Foundation Trust, London. She is a paediatric clinical geneticist with 24 years’ experience, predominantly in rare genetic disorders and in the care of children and families with life-limiting disorders. Her clinical and research interest is in paediatric neuromuscular and DNA repair disorders.

Shehla has a range of committee experience with a number of organisations, including her past role as expert clinical adviser to the UK Genetic Testing Network. She contributes to advisory bodies on policy development and implementation of new genomic technologies. As a former head of service of one of the largest regional genetics services, Shehla has extensive experience of negotiating the establishment of new services, implementing Highly Specialist Service clinics and devising novel models of service delivery.

Shehla has contributed to both service and national policy development such as UKGTN Guide to Centres with specialist expertise for rare genetic disorders, genomic medicine in the UK and input into national rare disease strategy.

Sara Payne


Lay member

Sara has professional and personal commitment to new treatments and medicines. She was an intellectual property solicitor and now focuses on the regulatory and ethical challenges for professionals and patients in emerging treatments. She works with healthcare bodies and a think-tank on genomics, AI, algorithms and synthetic data and ethical issues, such as potential bias. She focused on rare diseases and risks of pseudonymised patient data in clinical trials in her recent MA on Medical Ethics and Law at King’s College London.

Sara has her own experience of tackling the process of finding the right treatment with her own rare oligodendroglioma brain cancer. She sits on an ethical committee, volunteers at the National Brain Appeal and sat for a year observing the MHRA Board to promote the involvement of patients.

Angharad Shambler


Angharad is a Senior Public Health Strategist, leading on Health Protection and Population Health Improvement portfolio at Haringey Council. She has an MSc in Public Health and Health Promotion and is a registered UKPHR Public Health Practitioner and Assessor.

She has worked in a number of local authority public health teams, NHS regional teams and the private health sector, all with a focus on healthcare public health and health protection.

Professor Ed Wilson


Ed is associate professor of health economics and Health Policy at the University of Exeter, working with Peninsula Technology Appraisal Group (PenTAG), one of several academic research groups contracted to produce systematic reviews and economic analyses for NICE, the UK National Screening Committee and the National Institute for Health Research (NIHR) Health Technology Assessment programme.

He is a health economist with over 20 years’ experience working at the Universities of York, Cambridge and East Anglia, as well as some time working in industry. He has published over 100 peer-reviewed journal articles and book chapters and his research interests focus on decision analytic modelling, expert elicitation of parameters for models in the absence of robust data, and value of information analysis.

More information

Find out more about the committee and read papers from previous meetings.

About the highly specialised technologies evaluation committee

Get involved

Find out when HSTEC meetings are held and register to attend.

Attend a meeting